China SXT Pharmaceuticals, Inc.SXTCEarnings & Financial Report
Nasdaq
SXTC Q2 2026 Key Financial Metrics
Revenue
$626.6K
Gross Profit
$101.7K
Operating Profit
$-6.3M
Net Profit
$-6.4M
Gross Margin
16.2%
Operating Margin
-1011.7%
Net Margin
-1016.5%
YoY Growth
N/A
Financial Flow
China SXT Pharmaceuticals, Inc. Q2 2026 Financial Summary
China SXT Pharmaceuticals, Inc. reported revenue of $626.6K for Q2 2026, with a net profit of $-6.4M (-1016.5% margin). Cost of goods sold was $524.8K, operating expenses totaled $6.4M.
Key Financial Metrics
| Total Revenue | $626.6K |
|---|---|
| Net Profit | $-6.4M |
| Gross Margin | 16.2% |
| Operating Margin | -1011.7% |
| Report Period | Q2 2026 |
Income Statement
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | Q2 2026 | |
|---|---|---|---|---|---|
| Revenue | $1.0M | $1.2M | $939583 | $829490 | $626570 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | Q2 2026 | |
|---|---|---|---|---|---|
| Assets | $22.7M | $22.2M | $14.6M | $31.0M | $21.7M |
| Liabilities | $8.9M | $7.3M | $9.5M | $16.0M | $6.2M |
| Equity | $13.8M | $14.9M | $5.1M | $15.0M | $15.4M |
Cash Flow
| Q2 2022 | Q2 2023 | Q2 2024 | Q2 2025 | Q2 2026 | |
|---|---|---|---|---|---|
| Operating CF | $-312349 | $-549125 | $-579568 | $-1.4M | $-1.8M |